Biomarkers /
NUTM1
Overview
NUTM1 is altered in 0.37% of all cancers with lung adenocarcinoma, melanoma, skin squamous cell carcinoma, conventional glioblastoma multiforme, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in NUTM1 are NUTM1 Fusion (0.03%), NUTM1 P159L (0.06%), NUTM1 R203H (0.05%), NUTM1 S116L (0.05%), and NUTM1 R215H (0.04%) [3].
Clinical Trials
Significance of NUTM1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.